BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 9376591)

  • 1. Natural killer (NK) cells are functionally abnormal and NK cell progenitors are diminished in granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cell collections.
    Miller JS; Prosper F; McCullar V
    Blood; 1997 Oct; 90(8):3098-105. PubMed ID: 9376591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic and functional characterization of long-term culture-initiating cells present in peripheral blood progenitor collections of normal donors treated with granulocyte colony-stimulating factor.
    Prosper F; Stroncek D; Verfaillie CM
    Blood; 1996 Sep; 88(6):2033-42. PubMed ID: 8822922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor.
    Lemoli RM; Tafuri A; Fortuna A; Petrucci MT; Ricciardi MR; Catani L; Rondelli D; Fogli M; Leopardi G; Ariola C; Tura S
    Blood; 1997 Feb; 89(4):1189-96. PubMed ID: 9028941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer.
    Burns LJ; Weisdorf DJ; DeFor TE; Repka TL; Ogle KM; Hummer C; Miller JS
    Exp Hematol; 2000 Jan; 28(1):96-103. PubMed ID: 10658681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
    Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
    Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
    Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
    Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of the phenotype and proliferative capacity of peripheral blood (PB) CD34+ cells mobilized by four different protocols and those of steady-phase PB and bone marrow CD34+ cells.
    To LB; Haylock DN; Dowse T; Simmons PJ; Trimboli S; Ashman LK; Juttner CA
    Blood; 1994 Nov; 84(9):2930-9. PubMed ID: 7524760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of interleukin-3, interleukin-7, interleukin 15, and granulocyte-macrophage colony-stimulating factor in the generation of natural killer and B cells from primitive human fetal liver progenitors.
    Muench MO; Humeau L; Paek B; Ohkubo T; Lanier LL; Albanese CT; Bárcena A
    Exp Hematol; 2000 Aug; 28(8):961-73. PubMed ID: 10989197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primitive long-term culture initiating cells (LTC-ICs) in granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells have similar potential for ex vivo expansion as primitive LTC-ICs in steady state bone marrow.
    Prosper F; Vanoverbeke K; Stroncek D; Verfaillie CM
    Blood; 1997 Jun; 89(11):3991-7. PubMed ID: 9166837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colony-stimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor.
    Hess DA; Levac KD; Karanu FN; Rosu-Myles M; White MJ; Gallacher L; Murdoch B; Keeney M; Ottowski P; Foley R; Chin-Yee I; Bhatia M
    Blood; 2002 Aug; 100(3):869-78. PubMed ID: 12130497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of natural killer cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes.
    Clausen J; Enk M; Vergeiner B; Eisendle K; Petzer AL; Gastl G; Gunsilius E
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):691-7. PubMed ID: 15389435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor.
    Miller JS; Alley KA; McGlave P
    Blood; 1994 May; 83(9):2594-601. PubMed ID: 7513206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1992 Nov; 80(9):2182-7. PubMed ID: 1384796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
    Brugger W; Möcklin W; Heimfeld S; Berenson RJ; Mertelsmann R; Kanz L
    Blood; 1993 May; 81(10):2579-84. PubMed ID: 7683923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
    Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
    Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
    Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell alloreactivity induced by normal G-CSF-mobilized CD34+ blood cells.
    Rondelli D; Anasetti C; Fortuna A; Ratta M; Arpinati M; Bandini G; Lemoli RM; Tura S
    Bone Marrow Transplant; 1998 Jun; 21(12):1183-91. PubMed ID: 9674849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological characterization of CD34+ cells mobilized into peripheral blood.
    Lemoli RM; Tafuri A; Fortuna A; Catani L; Rondelli D; Ratta M; Tura S
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S47-50. PubMed ID: 9989890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion.
    Sosman JA; Stiff P; Moss SM; Sorokin P; Martone B; Bayer R; van Besien K; Devine S; Stock W; Peace D; Chen Y; Long C; Gustin D; Viana M; Hoffman R
    J Clin Oncol; 2001 Feb; 19(3):634-44. PubMed ID: 11157013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.